Executives of pharmaceutical, biotechnology and medical device companies must know and abide by myriad statutes and regulations. Laws governing the pricing, marketing and selling of health care products abound. Many carry stiff criminal penalties. And the federal government has aggressively investigated health care companies for alleged violations.

Not infrequently, a corporate entity has chosen to plead guilty to criminal violations rather than to risk conviction and debarment, which would prevent it from doing business with government agencies and bar others from receiving government reimbursement for using the company’s products. But the individual executives have long taken some comfort in the fact that most criminal laws only punish those who act with criminal intent.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]